A novel vasopressin peptide lowers blood pressure through decreases in cardiac output

Canadian Journal of Physiology and Pharmacology

Volumn 81, Issue 5, 2003, Pages 497-501

  Yu, Ming ^a   Ghosh, Mahua ^a   McNeill, J Robert ^a  

^a UNIVERSITY OF SASKATCHEWAN   (Canada)

Author keywords

Blood pressure; Cardiac output; Hypotensive peptide; Total peripheral resistance; Vasopressin

Indexed keywords

ANTIHYPERTENSIVE AGENT; ARGIPRESSIN DERIVATIVE; SYNTHETIC PEPTIDE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIHYPERTENSIVE ACTIVITY; ARTICLE; CONTROLLED STUDY; DOSE RESPONSE; DRUG EFFECT; DRUG INFUSION; HEART OUTPUT; HEMODYNAMICS; HYPERTENSION; MALE; NONHUMAN; PERIPHERAL CIRCULATION; PRESSURE TRANSDUCER; PRIORITY JOURNAL; RAT; RAT STRAIN; TELEMETRY;

ANIMALS; ANTIHYPERTENSIVE AGENTS; ARGININE VASOPRESSIN; BLOOD PRESSURE; CARDIAC OUTPUT; DOSE-RESPONSE RELATIONSHIP, DRUG; MALE; RATS; RATS, SPRAGUE-DAWLEY; VASCULAR RESISTANCE;

EID: 0037517161     PISSN: 00084212     EISSN: None     Source Type: Journal    
DOI: 10.1139/y03-054     Document Type: Article

References (11)

1. Balakrishnan, S., and McNeill, J.R. 1996. Cardiac output mediates the antihypertensive effect of vasopressin in spontaneous hypertension. Am. J. Physiol. 271: H1728-H1733.
2. Chan, W.Y., Levi, R., Wo, N.C., Koyama, M., Stoev, S., Cheng, L.L., and Manning, M. 2001. Novel selective hypotensive vasopressin peptides: cardiovascular and structure-activity-relationship studies. Eur. J. Pharmacol. 419: 65-72.
3. Chan, W.Y., Wo, N.C., Stoev, S., Cheng, L.L., and Manning, M. 1998. Discovery of novel selective hypotensive vasopressin peptides that exhibit little or no functional interactions with known oxytocin/vasopressin receptors. Br. J. Pharmacol. 125: 803-811.
4. Chiu, E.K.Y., and McNeill, J.R. 1987. Pretreatment with vasodilator or V1-antagonist abolishes vasopressin withdrawal hypotension in spontaneously hypertensive rats. J. Hypertens. 5: 593-598.
5. Chiu, E.K.Y., and McNeill, J.R. 1989. Withdrawal-induced antihypertensive effect of vasopressin in doca-salt hypertension. Am. J. Hypertens. 2: 458-461.
6. 1 arginine vasopressin agonist results in sustained hypertension. Am. J. Physiol. 267: H751-H756.
7. Lautt, W.W. 1989. Resistance or conductance for expression of arterial vascular tone. Microvasc. Res. 37: 230-236.
8. Liard, J.F. 1988. Characterization of acute hemodynamic effects of antidiuretic agonists in conscious dogs. J. Cardiovasc. Pharmacol. 11(2): 174-180.
9. Lohmeier, T.E., Smith, M.J., Jr., Cowley, A.W., Jr., Manning, R.D., and Guyton, A.C. 1981. Is vasopressin an important hypertensive hormone? Hypertension, 3: 416-425.
10. Manning, M., Stoev, S., Cheng, L.L., Wo, N.C., and Chan, W.Y. 1999. Discovery and design of novel vasopressin hypotensive peptide agonists. J. Recept. Signal Transduct. Res. 19: 631-644.
11. Yu, M., Gopalakrishnan, V., and McNeill, J.R. 2001. Role of endothelin and vasopressin in DOCA-salt hypertension. Br. J. Pharmacol. 132: 1447-1454.